Viewing Study NCT01232257



Ignite Creation Date: 2024-05-05 @ 11:02 PM
Last Modification Date: 2024-10-26 @ 10:27 AM
Study NCT ID: NCT01232257
Status: COMPLETED
Last Update Posted: 2012-10-26
First Post: 2010-11-01

Brief Title: Effect of N-acetylcysteine NAC on Hydrogen Sulfide H2S in Chronic Kidney Disease CKD
Sponsor: AC Abrahams
Organization: UMC Utrecht

Study Overview

Official Title: Effect of N-acetylcysteine on Hydrogen Sulfide in Chronic Kidney Disease
Status: COMPLETED
Status Verified Date: 2012-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Cardiovascular morbidity and mortality is high in CKD patients Nitric oxide NO deficiency plays a crucial role in progression of CKD This leads to endothelial dysfunction hypertension and inflammation Hydrogen sulfide H2S could serve as a backup mechanism for NO deficiency in CKD N-acetylcysteine NAC is a derivate of cysteine and this is the main substrate for H2S production Therefore NAC should enable us to stimulate H2S production in humans Our objective is to investigate the effect of NAC on plasma H2S levels and on markers of oxidative stress inflammation and endothelial dysfunction in healthy volunteers CKD patients and dialysis patients We hypothesize that there is an increase in H2S levels after treatment with NAC
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None